40.65

1.37% 0.55

After Hours: 39.90 -0.75 -1.85%

Artivion Inc (AORT)

Overview News Price History Option Chain Discussions Forecast Stock Split Dividend History

Artivion Inc stock is traded at $40.65, with a volume of 779.66K. It is up +1.37% in the last 24 hours and down -5.22% over the past month. Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Previous Close:

$40.10

Open:

$40.14

24h Volume:

779.66K

Relative Volume:

2.25

Market Cap:

$1.93B

Revenue:

$405.04M

Net Income/Loss:

$-17.90M

P/E Ratio:

-94.60

EPS:

-0.4297

Net Cash Flow:

$7.66M

1W Performance:

+3.02%

1M Performance:

-5.22%

6M Performance:

-7.30%

1Y Performance:

+36.18%

1-Day Range:

$39.55

$40.93

1-Week Range:

$39.08

$41.00

52-Week Range:

$21.97

$48.25

Artivion Inc Stock (AORT) Company Profile

Name

Artivion Inc

Sector

Healthcare (1112)

Industry

Medical Devices (141)

Phone

(770) 419-3355

Address

1655 ROBERTS BOULEVARD N W, KENNESAW

Employee

1,600

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

AORT's Discussions on Twitter

Compare AORT vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AORT Artivion Inc	40.65	1.90B	405.04M	-17.90M	7.66M	-0.4297
ABT Abbott Laboratories	111.47	197.52B	44.33B	6.48B	6.92B	3.7033
SYK Stryker Corp	365.85	139.09B	25.12B	3.25B	4.28B	8.4018
MDT Medtronic Plc	100.88	129.59B	34.76B	4.79B	5.21B	3.7017
BSX Boston Scientific Corp	74.12	108.96B	20.08B	2.89B	3.82B	1.9391
EW Edwards Lifesciences Corp	76.44	46.04B	6.07B	1.06B	799.60M	1.8527

Artivion Inc Stock (AORT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-13-25	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jun-17-25	Initiated	Canaccord Genuity	Buy
Oct-23-24	Initiated	JMP Securities	Mkt Outperform
Sep-27-22	Reiterated	Lake Street	Buy
Aug-08-22	Initiated	Lake Street	Buy
Mar-03-22	Initiated	Stifel	Buy

View All

Artivion Inc Stock (AORT) Latest News

Artivion Inc (AORT)

Artivion Inc Stock (AORT) Company Profile

Compare AORT vs ABT, SYK, MDT, BSX, EW

Artivion Inc Stock (AORT) Upgrades & Downgrades

Artivion Inc Stock (AORT) Latest News

Artivion Inc (AORT) Q4 2025 Earnings Call Highlights: Strong Rev - GuruFocus

Artivion Q4 Earnings Call Highlights - Yahoo Finance

Artivion Q4 2025 slides: double-digit growth across product lines, strong 2026 outlook By Investing.com - Investing.com South Africa

Artivion (AORT) Q4 2025 Earnings Call Transcript - The Globe and Mail

Artivion Q4 2025 slides: double-digit growth across product lines, strong 2026 outlook - Investing.com India

Earnings call transcript: Artivion Q4 2025 beats EPS forecast, stock rises - Investing.com

Artivion (NYSE:AORT) Misses Q4 CY2025 Sales Expectations - Finviz

Artivion (AORT) Q4 Earnings Surpass Estimates - Yahoo Finance UK

Artivion: Fourth Quarter Financial Highlights - Bitget

Artivion: Q4 Earnings Snapshot | State | mdjonline.com - Marietta Daily Journal

Artivion: Q4 Earnings Snapshot - kare11.com

Artivion (NYSE:AORT) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat

Earnings Flash (AORT) Artivion, Inc. Reports Q4 Revenue $116.0M, vs. FactSet Est of $116.5M - marketscreener.com

Artivion shares fall as Q4 revenue misses analyst estimates By Investing.com - Investing.com Australia

Artivion shares fall as Q4 revenue misses analyst estimates - Investing.com

Artivion Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire

MACD Signal: Will Artivion Inc stock go up in YEARWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn

Artivion earnings on deck: Can revenue growth offset profit concerns? By Investing.com - Investing.com Nigeria

Artivion earnings on deck: Can revenue growth offset profit concerns? - Investing.com

Artivion Becomes Oversold (AORT) - Nasdaq

Aug Wrap: Is Artivion Inc stock undervalued right nowSwing Trade & Real-Time Buy Zone Alerts - baoquankhu1.vn

What To Expect From Artivion's (AORT) Q4 Earnings - Finviz

What To Expect From Artivion’s (AORT) Q4 Earnings - TradingView

Is PDF Solutions Inc subject to activist investor interest2025 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn

Market Recap: Is Artivion Inc stock undervalued right now2025 Technical Patterns & Technical Pattern Alert System - baoquankhu1.vn

Artivion, Inc. (NYSE:AORT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

US Market Recap: Whats the beta of Artivion Inc stockTake Profit & AI Driven Stock Price Forecasts - baoquankhu1.vn

Artivion (AORT) to Release Earnings on Thursday - Defense World

Earnings Miss: Is Artivion Inc a momentum stockJuly 2025 Short Interest & AI Driven Price Predictions - baoquankhu1.vn

Aug Outlook: What is the long term forecast for Artivion Inc stock2025 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Sell Signal: Is Artivion Inc being accumulated by smart moneyJuly 2025 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn

Artivion, Inc. (AORT) Investor Outlook: Potential Upside Of 25.43% And Strong Buy Ratings - DirectorsTalk Interviews

Artivion reports positive clinical data from aortic arch trials By Investing.com - Investing.com Nigeria

The Analyst Verdict: Artivion In The Eyes Of 4 Experts - Benzinga

Needham Reiterates Buy Rating for Artivion (AORT) with $58 Targe - GuruFocus

Artivion (NYSE:AORT) Receives Buy Rating from Needham & Company LLC - MarketBeat

Artivion, Inc. Announces Presentation of Positive New Clinical Data from Endospan's Nexus Trial and its Amds PERSEVERE IDE Trial - marketscreener.com

Artivion (AORT) Unveils Promising Clinical Data from Key Trials - GuruFocus

Artivion reports positive clinical data from aortic arch trials - Investing.com

Artivion Announces Presentation of Positive New Clinical Data from NEXUS TRIOMPHE and AMDS PERSEVERE Trials at the 62nd Society of Thoracic Surgery Annual Meeting - PR Newswire

Artivion (AORT) Valuation Check After Recent Share Price Moves And Growth Outlook - Yahoo Finance UK

Market Outlook: Whats next for Artivion Inc stockWeekly Trade Analysis & Low Risk Investment Opportunities - baoquankhu1.vn

What is the long term forecast for Artivion Inc. stockWeekly Profit Summary & Free Community Consensus Stock Picks - mfd.ru

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter 2025 Financial Results - ChartMill

Aug Sentiment: Is Artivion Inc a momentum stockJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - baoquankhu1.vn

Aug Decliners: Is Artivion Inc stock undervalued right now2025 Market Outlook & AI Forecast for Swing Trade Picks - baoquankhu1.vn

Artivion (NYSE:AORT) Downgraded to Buy Rating by Wall Street Zen - MarketBeat

Artivion, Inc. (AORT) Stock Analysis: Unlocking a Potential 19% Upside in the Medical Devices Sector - DirectorsTalk Interviews

Are Options Traders Betting on a Big Move in Artivion Stock? - MSN

Relative Strength Alert For Artivion - Nasdaq

Artivion, Inc. (AORT) Stock Analysis: 20% Upside Potential and a Strong Buy Consensus Signal Opportunity for Investors - DirectorsTalk Interviews

Artivion Inc Stock (AORT) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to AORT